BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Shahid S, Prockop SE, Flynn GC, et al. (2025) Allogeneic Off-the-Shelf CAR T-Cell Therapy for Relapsed or Refractory B-Cell Malignancies. Blood Advances |
| Perica K, Jain N, Scordo M, et al. (2025) CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in . The New England Journal of Medicine. 392: 577-583 |
| Perica K, Kotchetkov I, Mansilla-Soto J, et al. (2025) HIV immune evasin Nef enhances allogeneic CAR T cell potency. Nature |
| Park JH, Palomba ML, Perica K, et al. (2025) Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2402424 |
| Haubner S, Subklewe M, Sadelain M. (2024) Honing CAR T cells to tackle acute myeloid leukemia. Blood |
| Sætersmoen M, Kotchetkov IS, Torralba-Raga L, et al. (2024) Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor. Med (New York, N.Y.) |
| Park J, Palomba ML, Perica K, et al. (2024) Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma. Research Square |
| Hammer Q, Perica K, Mbofung RM, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell Stem Cell |
| Shi Y, Kotchetkov IS, Dobrin A, et al. (2024) GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Martin KE, Hammer Q, Perica K, et al. (2024) Engineering immune-evasive allogeneic cellular immunotherapies. Nature Reviews. Immunology |